Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWOG S1007 adjuvant endocrine therapy with or without chemotherapy in node-positive HR-positive HER2-negative breast cancer
2024-516801-22-00Phase 3Authorised
- Sponsor
- Cancer Trials Ireland
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, anastrozole, docetaxel, doxorubicin, cyclophosphamide and 3 more in breast cancer (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Invasive disease-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
tamoxifenanastrozoledocetaxeldoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516801-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516801-22-00.